In addition to GLP-1R/GCGR dual agonists, a chimeric peptide as dual GLP-1/GIP receptor agonists has been developed, showing enhanced therapeutic potential for obesity and related comorbidities. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.